CA2254953A1 - Therapies for chronic renal failure - Google Patents

Therapies for chronic renal failure

Info

Publication number
CA2254953A1
CA2254953A1 CA002254953A CA2254953A CA2254953A1 CA 2254953 A1 CA2254953 A1 CA 2254953A1 CA 002254953 A CA002254953 A CA 002254953A CA 2254953 A CA2254953 A CA 2254953A CA 2254953 A1 CA2254953 A1 CA 2254953A1
Authority
CA
Canada
Prior art keywords
renal failure
chronic renal
therapies
risk
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002254953A
Other languages
French (fr)
Other versions
CA2254953C (en
Inventor
Kuber T. Sampath
Charles M. Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MARIEL THERAPEUTICS Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2254953A1 publication Critical patent/CA2254953A1/en
Application granted granted Critical
Publication of CA2254953C publication Critical patent/CA2254953C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-.beta. superfamily of proteins.
CA002254953A 1996-05-06 1997-05-06 Therapies for chronic renal failure Expired - Fee Related CA2254953C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
US08/643,321 1996-05-06
PCT/US1997/007655 WO1997041880A1 (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure

Publications (2)

Publication Number Publication Date
CA2254953A1 true CA2254953A1 (en) 1997-11-13
CA2254953C CA2254953C (en) 2006-09-26

Family

ID=24580305

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002254953A Expired - Fee Related CA2254953C (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure
CA002254954A Expired - Fee Related CA2254954C (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002254954A Expired - Fee Related CA2254954C (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Country Status (11)

Country Link
US (5) US6498142B1 (en)
EP (2) EP0914146B1 (en)
JP (4) JP2000510835A (en)
AT (2) ATE277629T1 (en)
AU (2) AU2832297A (en)
CA (2) CA2254953C (en)
DE (2) DE69723845T2 (en)
DK (2) DK0910400T3 (en)
ES (2) ES2203803T3 (en)
PT (2) PT914146E (en)
WO (2) WO1997041881A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
DK0980252T3 (en) 1997-05-05 2005-01-31 Curis Inc Therapies for acute renal failure
AU7473098A (en) * 1997-05-07 1998-11-27 Biogen, Inc. Novel therapies for cystic kidney disease
ATE220564T1 (en) 1997-08-14 2002-08-15 Sulzer Innotec Ag COMPOSITION AND DEVICE FOR REPAIRING CARTILAGE TISSUE IN VIVO CONSISTING OF NANOCAPSULES WITH OSTEOINDUCTIVE AND/OR CHONDROINDUCTIVE FACTORS
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
AU1706499A (en) * 1997-12-04 1999-06-16 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
WO2000006716A1 (en) * 1998-07-28 2000-02-10 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
DE60027907T2 (en) * 1999-09-14 2007-01-04 Biogen Idec Ma Inc., Cambridge THERAPIES FOR CHRONIC KIDNEY INUFFICIENCY USING ONE OR MORE INTEGRINANT AGONIST (DE)
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
AU2003268219B2 (en) * 2002-08-28 2009-09-24 Barnes-Jewish Hospital Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
EP2441474B1 (en) 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
CA2558029C (en) 2004-03-30 2013-05-07 Ilypsa, Inc. Ion binding polymers and uses thereof
JP2008500816A (en) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド BMP-7 variants with improved properties
US20100150885A1 (en) * 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
CA2629522A1 (en) 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
EP1978802A2 (en) * 2006-01-24 2008-10-15 Northfield Laboratories, Inc. Polymerized hemoglobin media and its use in isolation and transplantation of islet cells
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
ES2379603T3 (en) 2006-05-30 2012-04-27 Antibodyshop A/S Methods for rapid assessment of the severity of trauma
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
EP2047862B9 (en) 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Remedy for renal disease
EP2114390A2 (en) * 2006-12-15 2009-11-11 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
EP2148706A2 (en) * 2007-04-24 2010-02-03 Advanced Technologies and Regenerative Medicine, LLC Engineered renal tissue
DE102007034580B4 (en) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial based on a hydrophilic polymeric carrier
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
JP2011523357A (en) * 2008-05-06 2011-08-11 ジョスリン ダイアビーティス センター インコーポレイテッド Methods and compositions for inducing brown adipocyte differentiation
JP5485885B2 (en) * 2008-06-24 2014-05-07 株式会社根本杏林堂 Chemical injection device, fluoroscopic imaging system having this chemical injection device, computer program of chemical injection device, and data processing method
JP2012501456A (en) * 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2813848A3 (en) * 2008-08-29 2015-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3783363A1 (en) 2008-10-21 2021-02-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009308375B2 (en) * 2008-10-21 2015-06-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104330574B (en) 2008-11-10 2017-04-12 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5735922B2 (en) * 2008-11-22 2015-06-17 アスチュート メディカル，インコーポレイテッド Methods for the diagnosis and prognosis of kidney injury and renal failure
WO2010091231A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2396025A2 (en) 2009-02-12 2011-12-21 Stryker Corporation Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
CA2752160A1 (en) * 2009-02-12 2010-08-19 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including tgf-.beta. superfamily members
EP2406281B1 (en) 2009-03-12 2016-02-17 Haase Investments UG Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
BR112012002711A2 (en) 2009-08-07 2016-11-01 Astute Medical Inc method for assessing renal status in an individual, and protein medication
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
CA2779902A1 (en) 2009-11-07 2011-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (en) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2516456A1 (en) 2009-12-22 2012-10-31 Stryker Corporation Bmp-7 variants with reduced immunogenicity
NZ601590A (en) 2010-02-05 2014-10-31 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5998057B2 (en) 2010-02-26 2016-11-30 アスチュート メディカル，インコーポレイテッド Methods and compositions for diagnosis and prognosis of kidney injury and renal failure
ES2667066T3 (en) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York NGAL mutant proteins and uses thereof
CA2804297A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605561A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP2605787B1 (en) 2010-08-20 2017-04-26 Wyeth LLC Designer osteogenic proteins
ES2933570T3 (en) 2011-12-08 2023-02-10 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of kidney injury and kidney failure
JP6475624B2 (en) 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド Potassium binding agents for the treatment of hypertension and hyperkalemia
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
EP3734280B8 (en) 2013-01-17 2022-08-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
JP2016536588A (en) * 2013-11-11 2016-11-24 ゼネラル・エレクトリック・カンパニイ A method for reducing errors in rotor speed measurement.
EP2944326B1 (en) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases
AU2016218977C1 (en) 2015-02-13 2023-03-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2017214203A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN116115629A (en) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 Nucleic acid products and methods of administration thereof
JP2019039673A (en) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 Time digital conversion circuit, circuit device, physical quantity measuring device, electronic apparatus, and mobile entity

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (en) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti THERAPEUTIC APPLICATION OF CARNITINE AND SOME ACYLATED DERIVATIVES OF CARNITINE IN HEMODIALYSIS
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
DE69031939T2 (en) 1989-03-28 1998-09-10 Genetics Inst OSTEOINDUCTIVE COMPOSITIONS
WO1991018098A1 (en) 1990-05-16 1991-11-28 Genetics Institute, Inc. Bone and cartilage inductive proteins
JPH0426624A (en) * 1990-05-18 1992-01-29 Tsumura & Co Remedy for chronic renal failure
JPH05509086A (en) * 1990-06-22 1993-12-16 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー Treatment of chronic renal failure with imidazole angiotensin-2 receptor antagonists
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
ES2161693T3 (en) 1991-03-11 2001-12-16 Curis Inc MORPHOGENESIS INDUCED BY PROTEINS.
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
ES2156862T3 (en) 1991-08-30 2001-08-01 Curis Inc METHOD FOR SELECTING MORPHOGENIC PROTEINS.
ATE308336T1 (en) 1991-08-30 2005-11-15 Curis Inc OSTEOGENIC PROTEINS IN THE TREATMENT OF METABOLIC BONE DISEASES
JP3693338B2 (en) 1991-08-30 2005-09-07 キュリス インコーポレイテッド Regulation of inflammatory response by induction of tissue morphogenetic factor
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
CA2141556A1 (en) 1992-07-31 1994-02-17 Thangavel Kuberasampath Morphogen-enriched dietary composition
JP3981405B2 (en) 1992-07-31 2007-09-26 ストライカー・コーポレーション Morphogenic protein soluble complex and composition thereof
DE69333040T3 (en) 1992-07-31 2007-10-11 Curis, Inc., Cambridge MORPHOGEN INDUCED NERVES RESTORATION AND RECONSTRUCTION.
ES2114073T3 (en) 1992-09-16 1998-05-16 Creative Biomolecules Inc REGENERATION OF THE LIVER INDUCED BY MORPHOGEN.
CA2147598A1 (en) 1992-11-03 1994-05-11 Hermann Oppermann Op-3-induced morphogenesis
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
WO1994020539A1 (en) 1993-03-04 1994-09-15 Creative Biomolecules, Inc. Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
DE69431527T2 (en) * 1993-11-15 2003-06-26 Celtrix Pharma USE OF IGF-1 AND IGFBP-3 FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING A KIDNEY DISEASE
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
ATE493141T1 (en) * 1996-03-22 2011-01-15 Stryker Corp METHOD FOR IMPROVED FUNCTIONAL RECOVERY OF MOTOR COORDINATION, LANGUAGE OR SENSORY PERCEPTION AFTER CNS TRAUMA OR ISCHEMIA
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
AU2832297A (en) 1997-11-26
JP2000510124A (en) 2000-08-08
ES2230604T3 (en) 2005-05-01
US7524817B2 (en) 2009-04-28
CA2254954A1 (en) 1997-11-13
US8017580B2 (en) 2011-09-13
ES2203803T3 (en) 2004-04-16
PT910400E (en) 2003-12-31
DE69730966T2 (en) 2006-02-23
WO1997041880A1 (en) 1997-11-13
ATE277629T1 (en) 2004-10-15
US6498142B1 (en) 2002-12-24
US20050143304A1 (en) 2005-06-30
US20100291170A1 (en) 2010-11-18
AU2933997A (en) 1997-11-26
DK0910400T3 (en) 2003-11-24
ATE245997T1 (en) 2003-08-15
DK0914146T3 (en) 2005-01-31
PT914146E (en) 2005-02-28
WO1997041881A1 (en) 1997-11-13
US20120004171A1 (en) 2012-01-05
JP2000510835A (en) 2000-08-22
EP0914146B1 (en) 2004-09-29
EP0910400B1 (en) 2003-07-30
EP0910400A1 (en) 1999-04-28
CA2254954C (en) 2010-01-12
CA2254953C (en) 2006-09-26
DE69723845D1 (en) 2003-09-04
US8377878B2 (en) 2013-02-19
JP2012229268A (en) 2012-11-22
DE69730966D1 (en) 2004-11-04
DE69723845T2 (en) 2004-06-03
US6861404B1 (en) 2005-03-01
JP5247593B2 (en) 2013-07-24
EP0914146A1 (en) 1999-05-12
JP4766722B2 (en) 2011-09-07
JP2009185076A (en) 2009-08-20

Similar Documents

Publication Publication Date Title
CA2254953A1 (en) Therapies for chronic renal failure
DE69432582T2 (en) System for the administration of liquids in several patients
CA2345024A1 (en) Modified tgf-.beta. superfamily proteins
AU5561698A (en) Apparatus and system for the telematic control of physiological parameters of patients
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
NO970536D0 (en) Dispensed blood treatment system with oblique regulation interface
WO2000020607A3 (en) Chimaeric proteins between members of tgf-beta superfamily
AU1951195A (en) Combinations of thrombolytically active proteins and anticoagulants, and uses thereof
DK0980252T3 (en) Therapies for acute renal failure
NO972849D0 (en) Peptide p277 analogs and pharmaceutical compositions comprising these for the treatment or diagnosis of diabetes
DE69714451D1 (en) PRION-BINDING PROTEINS AND THEIR USE
WO2004019876A3 (en) Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
NO903844D0 (en) MEDICINAL DELIVERY MIXTURES BASED ON BIOLOGICAL CELLS OR COMPONENTS THEREOF AND PROCEDURES.
HK1055255A1 (en) Implant comprising immunologically isolated stromal cells and its use
ZA9710243B (en) 3-Amidochromanylsulfonyl(thio)ureas, processes for their preparation, their use, and pharmaceutical preparations comprising them.
NZ500216A (en) Beta-amyloid peptide-binding proteins and pharmaceutical use
EP1169058A4 (en) Insulin-like growth factor binding protein-4 protease
BR9713514A (en) New use of creatine
PT1214091E (en) THERAPIES FOR CHRONIC RENAL INSUFFICIENCY USING ONE OR MORE INTEGRIN ANTAGINISTS
AU644500B2 (en) 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
FR2729074B1 (en) SELF-BRAKING TAP NUT FOR ASSEMBLING RECONSTRUCTIVE SURGERY APPARATUS, ESPECIALLY IN SPINAL OSTEOSYNTHESIS
PT999849E (en) UTILIZATION OF LBP IN TREATMENT OF SEPTICEMIA
WO1999046381A3 (en) Human fgf gene and gene expression products
ZA9711270B (en) Precursory forms and new analogues of camptothecin, the processes for their preparation, their medical application and the pharmaceutical substances that contain them.
XJHuang Placental Intravenous Immunoglobulin (PtIVIG) for Treatment of Chronic Graft Versus Host Disease (CGVHD)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170510